Complex containing betaine, transition metal and sulfate in a ratio of 1:1:1, the transition metal being coordinated with two oxygen atoms from the betaine.

Subject matter of the invention are lead-free initiating agents or initiating agent mixtures and initiating and igniting compositions which contain the lead-free initiating agents or initiating agent mixtures.

The present invention relates to a composition for use in preventing migration of cancer cells in a subject known or suspected to suffer from cancer, the composition comprising at least one metal complex having the structure (I), formula (I), wherein M is a metal, preferably selected from the group consisting of copper, iron, manganese and zinc, X is X.sup.a or X.sup.b, wherein X.sup.a is selected from the group consisting of O, S and —N(R.sup.1)—, wherein R.sup.1 is H or alkyl, and wherein X.sup.b is a group forming a coordinate covalent bond to a second metal M′, preferably a group O, S or —N(R.sup.1)—, wherein M′ is preferably selected from the group consisting of copper, iron, manganese and zinc, and wherein M′ and M may be the same or different and are preferably the same, Z.sup.1 and Z.sup.2 are independently of each other a, substituted or unsubstituted, -Aryl-O—, -Aryl-N— or heteroaryl group, Y is Y.sup.a or Y.sup.b, wherein Y.sup.a is selected from the group consisting of H, alkyl, —OH, —SH, halogen, and —NR.sup.3R.sup.4, wherein R.sup.3 and R.sup.4, are independently of each other selected from H and alkyl, preferably R.sup.3 and R.sup.4 are both H, and wherein Y.sup.b is a group forming a coordinate covalent bond to M or M′, preferably Y.sup.b is a group O, S or —N(R.sup.Yb1R.sup.Yb2), wherein R.sup.Yb1 and R.sup.Yb1, are, independently of each other, H or alkyl, preferably H, and wherein n and m are integers, which are independently of each other, 0 or 1, Y.sup.2 is water or a halogen, and wherein Y.sup.3 is water or a halogen. The present invention further relates to a combined preparation comprising the aforesaid composition as well as to an in vitro method, for determining whether cancer cells are susceptible to immobilizing by the aforesaid compound.

##STR00001##

A highly pure form of ferric citrate and an industrially viable and advantageous process for its preparation are described.

##STR00001##

Oxo-nitrogenated iron complex having general formula (I): in which: R.sub.1 and R.sub.2, identical or different, represent a hydrogen atom; or they are selected from linear or branched, optionally halogenated C.sub.1-C.sub.20, preferably C.sub.1-C.sub.15, alkyl groups, optionally substituted cycloalkyl groups, optionally substituted aryl groups; R.sub.3 represents a hydrogen atom, or it is selected from linear or branched, optionally halogenated C.sub.1-C.sub.20, preferably C.sub.1-C.sub.15 alkyl groups, optionally substituted cycloalkyl groups, optionally substituted aryl groups; X, identical or different, represent a halogen atom such as, for example, chlorine, bromine, iodine, preferably chlorine; or they are selected from. linear or branched C.sub.1-C.sub.20, preferably C.sub.1-C.sub.15, alkyl groups, —OCOR.sub.4 groups or —OR.sub.4 groups in which R.sub.4 is selected from linear or branched C.sub.1-C.sub.20, preferably C.sub.1-C.sub.15, alkyl groups; n is 2 or 3. Said oxo-nitrogenated iron complex having general formula (I) can be advantageously used in a catalytic system for the (co)polymerization of conjugated dienes. ##STR00001##

An adsorbate-selective metal organic framework includes a transition metal; and a plurality of organic molecules coordinated to the transition metal so as to preserve open coordination sites for selectively adsorbing molecules that have low-lying π* orbitals. The transition metal has a lowest energy spin state in the presence of the selectively adsorbed molecules that are strongly bonding to the transition metal through π-donating interactions which is different than the lowest energy spin state in the absence of these adsorbed molecules. The transition metal has also a lowest energy spin state in the presence of non-selected molecules that are weakly bonding to the transition metal through σ- and/or π-accepting and/or donating interactions.

Provided herein are photochemical separations. The methods herein can include exposing a first metal complex and a second metal complex to light to facilitate an irreversible chemical reaction to form a modified first metal complex. The modified first metal complex then may be separated from the second metal complex. Compositions also are provided.

The present invention provides a compound comprising a moiety of the formula: (I) where said moiety of formula I is a radical, a cation, or a radical dication; Y.sup.1, Y.sup.2, Y.sup.3, R.sup.1a, R.sup.1b, R.sup.1c, R.sup.1d, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.2d, R.sup.3a, R.sup.3b, R.sup.3c, and R.sup.3d are as defined herein. Compounds containing a moiety of Formula I are useful in a wide variety of applications including, but not limited to, as photocatalysts, use in OLEDs, in electronic components, etc. As an organic-based photocatalysts, compounds containing a moiety of Formula I are activated by a relatively low energy electromagnetic wavelength, e.g., wavelength of 600 nm or greater. Furthermore, compounds of the invention can be used as both photoreduction catalysts and photooxidation catalysts.

##STR00001##

A magnetic resonance imaging (MRI) contrast agent and a preparation method and a use thereof is provided, which belong to the technical field of Magnetic Resonance Imaging contrast agent. The MRI contrast agent is prepared by the compound having a structure of formula I; and it also may include the compound having a structure of formula II or a pharmaceutically acceptable salt thereof, wherein M.sub.1 is a divalent ion or a trivalent ion of a paramagnetic metal selected from Mn, Fe, Eu, or Dy; M.sub.2 is selected from Na.sup.+, K.sup.+ or meglumine cation; when M.sub.1 is a divalent ion, a is 2; when M.sub.1 is a trivalent ion, a is 3. The MRI contrast agent has good water solubility, high relaxivity, and low toxic and side effect.

##STR00001##

An object of the present invention is to provide a novel metal-organic framework with a dicarboxylic acid having a terphenyl skeleton as an organic ligand and a gas storage method using such a metal-organic framework. A metal-organic framework comprising a carboxylate ion of formula (I) and a multivalent metal ion bonded to each other. (In formula (I), R.sup.1 and R.sup.2 each independently are a hydroxy group or an unsubstituted or substituted C1-6 alkyl group. R.sup.10 and R.sup.11 each independently are an unsubstituted or substituted C1-6 alkyl group. R.sup.20 is an unsubstituted or substituted C1-6 alkyl group. Provided that, as substituents on R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.10, R.sup.11, and R.sup.20, a carboxy group (COOH) and a carboxylate ion group (COO—) are excluded. In addition, R.sup.10 and R.sup.11 are not a methyl group at the same time.)

##STR00001##